ACE and myocardial ischemia: Therefore, despite the detrimental effects of sympathetic overactivation and the significant role of angiotensin II in IHD pathogenesis advancements in pharmacotherapy, such as ACE inhibitors, ARBs and novel interventions targeting the muscarinic receptors, offer promising avenues for mitigating myocardial pyroptosis and improving functional outcomes in IHD‐related conditions.